Trial Profile

Bictegravir, Emtricitabine and Tenofovir Alafenamide in Transwomen for Optimization of ART: The (mo)BETTA Trial

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir alafenamide
Indications HIV infections
Focus Adverse reactions; Therapeutic Use
Acronyms (mo)BETTA

Most Recent Events

24 Jan 2022 Status changed from recruiting to discontinued.
26 Apr 2021 Planned End Date changed from 1 Apr 2020 to 1 May 2022.
26 Apr 2021 Planned primary completion date changed from 1 Apr 2020 to 1 May 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com